Introduction Unilabs is the largest provider of medical laboratory diagnostics for prescribers and hospitals in... with medical professionals. Educational Background: You have a scientific or paramedical education with several years...
Numéro de référence: 52106 En tant que plus grand réseau médical de Suisse, nous fixons des normes avec nos cliniques, nos centres de chirurgie... : connaitre Mediway VOTRE PROFIL CFC ou diplôme DFMS d'assistant·e médical·e avec une expérience confirmée dans...
and biostatistics, or equivalent skills through demonstrated experience. Substantial experience in pharmaceutical, medical devices... (SDTM, ADaM) and OMOP are an advantage. Interest in analyzing big datasets such as electronic medical records using machine...
, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life... managerial experience are preferred. A minimum of seven to ten years of successful work experience in the medical device...
Indian benchmark indices continue bullish streak, fueled by potential rate cut by US Federal Reserve, FPI inflows, and rally in banking and IT stocks. Nifty 50 ends week with 1.30% gain, hitting new all-time high. Mid- and small-cap stocks also show strong performance. Continue Reading »
According to data collected from the Bombay Stock Exchange (BSE) website, the Emcure Pharmaceuticals IPO issue was oversubscribed 67.86 times. Qualified institutional buyers (QIB), non-institutional investors (NII), and retail investors showed strong bids on the third day. Continue Reading »
Anand Rathi recommends 2 'emerging picks' for July 2024, focusing on CONCOR and ideaForge Technology with a time horizon of 30-90 days. Continue Reading »
Stock Market Today: Sun Pharma share price has risen almost 25% year to date. The news flow recently has remained around regulatory actions by the USFDA for Dadra nd Halol plant Should you Buy , Sell or Hold the stock? Continue Reading »
Bansal Wire IPO subscription status shows overwhelming response from investors, with 59.57 times subscription. QIBs, NIIs, and retail investors actively participated. Price band set at ₹243-256 per share. Analysts bullish on long-term prospects, expecting decent listing gains of over 25%. Continue Reading »
V-Mart acquired Limeroad in FY23 to push its omnichannel strategy, but has been cutting costs to reduce Limeroad’s losses of late..Limeroad’s Ebitda loss in FY24 stood at ₹71.6 crore and V-Mart expects the FY25 loss to be 40-50% of that. Continue Reading »